Filing Flows

Filing Flows › Companies › Aytu Biopharma › Cash flow

Aytu Biopharma cash flow, quarter by quarter

Latest: Q4 FY26 · from the cash-flow statements filed with the SEC

Free cash flow$4.4M in Q4 FY26

Operating cash flow$4.4M
Capital spending−$12K
Free cash flow+$4.4M
Cash conversion cycle52 days

Analysis

In Q4 FY26, Aytu Biopharma generated $4.4M of operating cash flow and spent $12K on capital projects, leaving free cash flow of $4.4M. That is $1.6M more than in Q4 FY25 ($2.8M).

Operating cash flow was $4.4M against net income of −$15K. The largest differences: prepaid and other assets +$2.8M, payables −$1.9M, receivables +$1.7M.

Its cash conversion cycle was 52 days (receivables 134 + inventory 114 − payables 196).

Free cash flow

Aytu Biopharma: free cash flow by quarterAytu Biopharma: free cash flow by quarter−$1.3MQ1 FY25$2.9MQ2 FY25−$6.5MQ3 FY25$2.8MQ4 FY25−$618KQ1 FY26$3.7MQ2 FY26−$4.2MQ3 FY26$4.4MQ4 FY26
Operating cash flow less capital spending.
Aytu Biopharma: operating cash flow against capital spendingAytu Biopharma: operating cash flow against capital spendingOperating cash flowCapital spending−$1.2M$136KQ1 FY25$2.9M$6KQ2 FY25−$6.5M$69KQ3 FY25$2.8M$17KQ4 FY25−$618K$0Q1 FY26$3.7M$17KQ2 FY26−$4.2M$0Q3 FY26$4.4M$12KQ4 FY26
Latest (Q4 FY26): Operating cash flow $4.4M, Capital spending $12K.

Capital allocation, year by year

Aytu Biopharma: where the cash came from (up) and went (down), by fiscal yearAytu Biopharma: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingFY22: Operating cash flow −$28.8MFY22: Net borrowing −$9.4MFY22: Shares issued $11.7M$11.7MFY22FY23: Operating cash flow −$5.1MFY23: Net borrowing −$2.4MFY23: Shares issued $15.6M$15.6MFY23FY24: Operating cash flow −$1.4MFY24: Net borrowing −$2.0MFY24: Capital spending −$329KFY24FY25: Operating cash flow −$1.9MFY25: Net borrowing $6.7MFY25: Asset sales $668KFY25: Capital spending −$228K$7.3MFY25FY26: Operating cash flow $3.3MFY26: Net borrowing −$4.8MFY26: Capital spending −$29K$3.3MFY26
Over these 5 years operating cash flow totalled −$34.0M; the largest uses were operating cash flow ($37.3M) and net borrowing ($18.7M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$26.3M
Debt$11.0M
Net cash$15.3M
Due within a year$1.9M

Aytu Biopharma funds itself: free cash flow was — over the last twelve months, and $26.3M of cash and investments stands against $11.0M of debt ($1.9M due within a year, 14.2× covered by cash).

Aytu Biopharma: debt maturities by year (FY26)Aytu Biopharma: debt maturities by year (FY26)$1.9MYear 1$1.9MYear 2$7.4MYear 3
Principal due in each year as disclosed in the annual report, against $26.3M of cash and investments now.

Where the cash came from and went

Aytu Biopharma: sources (+) and uses (−) of cash, Q4 FY26Aytu Biopharma: sources (+) and uses (−) of cash, Q4 FY26Net borrowing (+) / repaid (−)−$4.8MOperating cash flow$4.4MCash drawn (+) / kept (−)$407KCapital spending−$12K

From profit to cash

Aytu Biopharma: net income to operating cash flow, Q4 FY26Aytu Biopharma: net income to operating cash flow, Q4 FY26Net income−$15KDepreciation & amortization$1.1MStock-based pay$146KReceivables$1.7MInventory$179KPayables−$1.9MAccrued liabilities$935KPrepaid and other assets$2.8MOther operating capital−$54KOperating cash flow$4.4M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q4 FY2613411419652
Q3 FY2620115125795
Q2 FY26195156221129
Q1 FY26213211224199
Q4 FY25201210211200
Q3 FY25149176189137
Q2 FY25138193213118
Q1 FY25130239239130

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Cash drawn (+) / kept (−)Free cash flow
Q4 FY26$4.4M−$12K−$4.8M$407K$4.4M
Q3 FY26−$4.2M—$872K$3.3M−$4.2M
Q2 FY26$3.7M−$17K−$6.3M$2.6M$3.7M
Q1 FY26−$618K—$5.3M−$1.7M−$618K
Q4 FY25$2.8M−$17K−$1.4M−$12.8M$2.8M
Q3 FY25−$6.5M−$69K$5.6M$2.2M−$6.5M
Q2 FY25$2.9M−$6K−$723K−$290K$2.9M
Q1 FY25−$1.2M−$136K$1.4M−$102K−$1.3M

Aytu Biopharma: income statement and cash flow

Aytu Biopharma, Q4 FY26: revenue $16.1M (+6% year over year), operating margin -4.8%. The chart follows the revenue to costs, profit and cash.

Aytu Biopharma: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.